RecruitingPhase 2NCT06161974
Study of Olutasidenib and Temozolomide in HGG
Studying Anaplastic astrocytoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Rigel Pharmaceuticals
- Principal Investigator
- Santosh Valvi, FRACP, MScPerth Children's Hospital
- Intervention
- Olutasidenib + TMZ(drug)
- Enrollment
- 60 enrolled
- Eligibility
- 12-39 years · All sexes
- Timeline
- 2025 – 2035
Study locations (18)
- Children's Hospital Colorado, Aurora, Colorado, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- Susan Chi, Boston, Massachusetts, United States
- Duke University Health System, Durham, North Carolina, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Texas Children's Hospital, Houston, Texas, United States
- Seattle Children's Hospital, Seattle, Washington, United States
- Sydney Children's Hospital, Randwick, New South Wales, Australia
- Queensland Children's Hospital, South Brisbane, Queensland, Australia
- Perth Children's Hospital, Perth, Western Australia, Australia
- The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada
- Montreal Children's Hospital, Montreal, Quebec, Canada
- +3 more locations on ClinicalTrials.gov
Collaborators
Nationwide Children's Hospital
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06161974 on ClinicalTrials.govOther trials for Anaplastic astrocytoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNCT07448480Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant GliomasBlokhin's Russian Cancer Research Center
- RECRUITINGEARLY PHASE1NCT06333899Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK FusionNationwide Children's Hospital
- RECRUITINGPHASE1, PHASE2NCT05956821Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of AgeUniversity of Miami
- ACTIVE NOT RECRUITINGPHASE1NCT06614855A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant GliomaJames Markert, MD
- RECRUITINGPHASE2NCT05843253Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutantNationwide Children's Hospital
- RECRUITINGNCT05839379Targeted Pediatric High-Grade Glioma TherapyNationwide Children's Hospital
- RECRUITINGPHASE2NCT06264388DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic AstrocytomaAshish Shah
- RECRUITINGPHASE1NCT05698524A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent GliomaUniversity of Nebraska